A recent study showed that malignant pediatric medulloblastomas do not show profound changes at the genomic and transcriptomic levels, however, using MS‐based phosphoproteomics, substantial differences were found.86 The proteomic data classified the medulloblastoma patients into subgroups, in which phosphorylation sites of MYC were associated with poor outcomes. Here, MYC is linked to medulloblastoma.